"Start with Integrity, Succeed with Action" Developing highquality biopharmaceuticals that ordinary people can afford is Innovent's mission and goal. Founded in , Innovent Biologics is committed to the research, development, production and commercialization of innovative drugs in major disease areas such as oncology, autoimmunity, metabolism, ophthalmology, etc., so that our work can benefit more lives.
The company has products approved for marketing, including sintilimab injection Daboshu®, bevacizumab injection Dayoutong®, adalimumab injection Sulixin®, rituximab injection Dabohua®, pemigatinib tablets Dabotan®, orebactinib tablets Nailik®, ramucirumab injection Ciranze®, sepretib capsules Ruitu®, ikiorencel injection Focus®, tolcizumab injection Symbile®, fuzelacept tablets Dabot®, pitubutinib tablets Jepali® and talentinib capsules Dabolu®. At present, there are varieties under review by NMPA, new drug molecules have entered Phase III or key clinical studies, and another new drug varieties have entered clinical research.
The company has entered into more than strategic collaborations with switzerland phone number list international partners including Eli Lilly, Roche, Sanofi, Adimab, Incyte and MD Anderson Cancer Center. While continuously developing innovative drugs and pursuing its own development, Innovent Biologics adheres to the development philosophy of putting people at the center of economic construction. Over the years, we have always been scientific and kind, adhered to the "patientcentered" principle, cared about patients and their families, and actively fulfilled our social responsibilities.